BLFS Biolife Solutions (BLFS) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0000834365
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
141
13F, latest reported quarter
What the filings say about BLFS
Insiders, 180 days
-$28.1M net sold
1 seller · 0% of sales under a 10b5-1 plan
Biolife Solutions insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BIOLIFE SOLUTIONS INC insiders sold a net $28.1M of stock across 557 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 5 earlier Form 4 trades (code P or S) here by this insider (3 buys, 2 sales), the last on May 20, 2026.
- -44.0% median (-42.7% mean) 90-day return after 3 previous buys.
- The trade is 13.7% of the 4,757,165 shares held after it.
- No other insider sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Casdin Partners Master Fund, L.P. sold about $15.4M of BLFS on May 21, 2026; 141 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (3 buys, 1 sale), the last on May 19, 2026.
- -44.0% median (-42.7% mean) 90-day return after 3 previous buys.
- The trade is 4.6% of the 5,407,165 shares held after it.
- No other insider sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Casdin Partners Master Fund, L.P. sold about $5.9M of BLFS on May 20, 2026; 141 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on May 18, 2023.
- -44.0% median (-42.7% mean) 90-day return after 3 previous buys.
- The trade is 5.3% of the 5,657,165 shares held after it.
- No other insider sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Casdin Partners Master Fund, L.P. sold about $6.8M of BLFS on May 19, 2026; 141 funds added in the latest 13F quarter.Context
- 70 earlier Form 4 trades (code P or S) here by this insider (70 sales), the last on Mar 9, 2026.
- The trade is 2.4% of the 108,758 shares held after it.
- 5 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Quality and Operations Foster Karen A. sold about $49.4K of BLFS on Mar 23, 2026; 5 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.Context
- 69 earlier Form 4 trades (code P or S) here by this insider (69 sales), the last on Mar 5, 2026.
- The trade is 0.4% of the 113,242 shares held after it.
- 5 other insiders sold within 30 days.
- 141 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Quality and Operations Foster Karen A. sold about $10.0K of BLFS on Mar 9, 2026; 5 other insiders sold within 30 days and 141 funds added in the latest 13F quarter.557 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$28.1M over 180 days
-$28.1M of it by a 10%+ holder
below 95% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
141 funds bought in last quarter
more than 72% of Medical Devices
Revenue
+28.9% year over year
more than 79% of Medical Devices
Margin
-4.8% net margin
more than 63% of Medical Devices
Buybacks
no share repurchases reported
Short interest
10.0% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
more than 81% of Medical Devices
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 3 in the prior 90
Why it matters
The absence is the signal: 3 sales in one 90-day window and none in the next is a change of behaviour, not a filing.
Watch BLFS
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+40.2%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BLFS: institutional holders (13F)
13F holdings, latest reported quarter
6,375,545 sh
$180.0M
4,655,000 sh
$131.5M
2,240,423 sh
$63.3M
1,964,084 sh
$55.5M
1,655,927 sh
$46.8M
Congress trades in BLFS
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BLFS planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BLFS mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ranger Micro Cap Fund
$297.9K position · as of 2026-07-31
2.6%
ALGER SMALL CAP FOCUS FUND
$16.7M position · as of 2026-07-31
2.0%
Rockefeller US Small Cap Core Fund
$1.8M position · as of 2026-05-31
1.8%
Royce Smaller-Companies Growth Fund
$4.1M position · as of 2026-06-30
1.7%
MOA SMALL CAP GROWTH FUND
$8.1M position · as of 2026-06-30
1.6%
Buffalo Early Stage Growth Fund
$1.2M position · as of 2026-06-30
1.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Roderick de Greef
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$7.0M
$12.4M
$1.7M
+60%
+9%
2023
$5.3M
$4.7M
$1.4M
+0%
+0%
2022
$4.7M
$5.4M
$1.8M
+12%
+24%
2021
$2.2M
$7.3M
$1.0M
+130%
+92%
2020
$1.5M
$6.5M
$1.4M
+147%
+87%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $28.1M sold by insiders over 180 days, 141 funds added last quarter. Each figure is a federal filing, dated the day it went public.
BLFS financials
Revenue growth
+28.9%
XBRL, annual
Net margin
-4.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$102.8M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BLFS
| FY Dec 2025 | $96.2M |
| FY Dec 2024 | n/a |
| FY Dec 2023 | $143.3M |
| FY Dec 2022 | $161.8M |
| FY Dec 2021 | $119.2M |
| Jun 2026 | $28.5M |
| Mar 2026 | $27.5M |
| Dec 2025 | $18.8M |
| Sep 2025 | $28.1M |
| Jun 2025 | $25.4M |
| Mar 2025 | $23.9M |
| Dec 2024 | -$3.4M |
| Sep 2024 | $30.6M |
At each fiscal year end
Single quarter
Net margin, TTM
+56.4%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BLFS
| FY Dec 2025 | -4.8% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | -47.5% |
| FY Dec 2022 | -86.4% |
| FY Dec 2021 | -7.5% |
| Jun 2026 | +158.4% |
| Mar 2026 | +4.3% |
| Dec 2025 | +58.9% |
| Sep 2025 | +2.2% |
| Jun 2025 | -62.3% |
| Mar 2025 | -1.9% |
| Dec 2024 | n/a |
| Sep 2024 | -5.6% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM BLFS
| FY Dec 2025 | n/a |
| FY Dec 2024 | $2.0M |
| FY Dec 2023 | -$18.9M |
| FY Dec 2022 | -$18.9M |
| FY Dec 2021 | -$13.0M |
| Jun 2026 | $5.3M |
| Mar 2026 | -$658.0K |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | $5.6M |
| Mar 2025 | $1.6M |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
0.00x
LongTermDebt as filed 2026-06-30 (includes the current portion); equity 2026-06-30
Debt to equity BLFS
| FY Dec 2025 | 0.01x |
| FY Dec 2024 | 0.05x |
| FY Dec 2023 | 0.07x |
| FY Dec 2022 | 0.07x |
| FY Dec 2021 | 0.02x |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.01x |
| Dec 2025 | 0.01x |
| Sep 2025 | 0.02x |
| Jun 2025 | 0.03x |
| Mar 2025 | 0.04x |
| Dec 2024 | 0.05x |
| Sep 2024 | 0.06x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt BLFS
| FY Dec 2025 | 4.03x |
| FY Dec 2024 | 0.53x |
| FY Dec 2023 | -0.52x |
| FY Dec 2022 | -0.33x |
| FY Dec 2021 | -0.64x |
| Jun 2026 | n/a |
| Mar 2026 | 7.16x |
| Dec 2025 | 4.03x |
| Sep 2025 | 2.25x |
| Jun 2025 | 1.55x |
| Mar 2025 | 1.13x |
| Dec 2024 | 0.53x |
| Sep 2024 | 0.45x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+15.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BLFS
| FY Dec 2025 | -1.3% |
| FY Dec 2024 | -5.9% |
| FY Dec 2023 | -19.4% |
| FY Dec 2022 | -33.2% |
| FY Dec 2021 | -2.6% |
| Jun 2026 | +15.1% |
| Mar 2026 | -0.8% |
| Dec 2025 | -1.3% |
| Sep 2025 | -0.9% |
| Jun 2025 | -1.7% |
| Mar 2025 | -3.0% |
| Dec 2024 | -5.9% |
| Sep 2024 | -14.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+13.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BLFS
| FY Dec 2025 | -1.1% |
| FY Dec 2024 | -5.0% |
| FY Dec 2023 | -15.8% |
| FY Dec 2022 | -27.8% |
| FY Dec 2021 | -2.3% |
| Jun 2026 | +13.9% |
| Mar 2026 | -0.7% |
| Dec 2025 | -1.1% |
| Sep 2025 | -0.8% |
| Jun 2025 | -1.5% |
| Mar 2025 | -2.6% |
| Dec 2024 | -5.0% |
| Sep 2024 | -12.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on invested capital BLFS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
the filed year and its quarters do not reconcile, so the trailing figure is withheld
Return on capital employed BLFS
| FY Dec 2025 | n/a |
| FY Dec 2024 | -1.2% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -1.3% |
| FY Dec 2021 | -9.6% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | -4.5% |
| Jun 2025 | -4.7% |
| Mar 2025 | -0.5% |
| Dec 2024 | -1.2% |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
33.00x
close 2026-10-07 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing BLFS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 24.14x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.9B
market value at close 2026-10-07 on 2026-07-30 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value BLFS
| FY Dec 2025 | $1.1B |
| FY Dec 2024 | $1.1B |
| FY Dec 2023 | $711.5M |
| FY Dec 2022 | $784.5M |
| FY Dec 2021 | $1.5B |
| Jun 2026 | $1.4B |
| Mar 2026 | $901.2M |
| Dec 2025 | $1.1B |
| Sep 2025 | $1.2B |
| Jun 2025 | $1.0B |
| Mar 2025 | $1.0B |
| Dec 2024 | $1.1B |
| Sep 2024 | $1.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield BLFS
| FY Dec 2025 | n/a |
| FY Dec 2024 | +0.2% |
| FY Dec 2023 | -2.6% |
| FY Dec 2022 | -2.4% |
| FY Dec 2021 | -0.8% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | +0.2% |
| Sep 2024 | +0.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing BLFS
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-07. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $96.2M | $82.3M | $143.3M | $161.8M |
| Gross profit | $62.1M | $50.1M | $41.3M | n/a |
| Operating income | -$16.6M | -$4.5M | -$17.2M | -$5.9M |
| Net income | -$4.6M | -$20.2M | -$68.0M | -$139.8M |
| EPS (diluted) | -0.10 | -0.44 | -1.55 | -3.25 |
| Operating cash flow | $20.1M | $8.4M | -$12.5M | -$8.5M |
| Cash | $33.0M | $91.5M | $27.9M | $19.4M |
| Long-term debt | $0 | $5.0M | $17.6M | $23.8M |
SEC XBRL, fiscal years, as known on 2026-10-27
BLFS Stock Sonar score 6/7 axes
Find similar shapesCompareBLFS ranks highest on financial health (99th percentile) and profitability (88th), and lowest on insider conviction (3rd), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BLFS filings, in plain words
Are Biolife Solutions insiders buying or selling BLFS?
In the 180 days to 2026-10-27, Biolife Solutions insiders were net sellers, a net $28.1M across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-27, Biolife Solutions insiders were net sellers of BLFS, a net $28.1M across purchases and sales reported on Form 4 by 1 seller. Most of that figure, $28.1M, came from a holder of 10% or more rather than an officer or director. None of the 3 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
